Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Boger

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|October 1, 1985
Antimicrobial and cytotoxic properties of 9,10-dihydrophenanthrenes: structure-activity studies on juncusolD L Boger, L A Mitscher, M D Mullican, et al.
Bioorganic & Medicinal Chemistry|September 26, 2000
Assessment of solution-phase positional scanning libraries based on distamycin A for the discovery of new DNA binding agentsD L Boger, M A Dechantsreiter, T Ishii, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 1999
Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicityP G Baraldi, B Cacciari, R Romagnoli, et al.
Journal of the American Chemical Society|June 21, 2001
A simple, high-resolution method for establishing DNA binding affinity and sequence selectivityD L Boger, B E Fink, S R Brunette, et al.
Bioorganic & Medicinal Chemistry|July 1, 1993
Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunitD L Boger, D S Johnson, M S Palanki, et al.
Bioorganic & Medicinal Chemistry|November 14, 1997
Functionalized analogues of 5,8,10-trideazafolate: development of an enzyme-assembled tight binding inhibitor of GAR Tfase and a potential irreversible inhibitor of AICAR TfaseD L Boger, N E Haynes, M S Warren, et al.
Bioorganic & Medicinal Chemistry|November 14, 1997
Multisubstrate analogue based on 5,8,10-trideazafolateD L Boger, N E Haynes, M S Warren, et al.
Biochemistry|December 22, 1999
New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with beta-GAR and 10-formyl-5,8,10-trideazafolic acidS E Greasley, M M Yamashita, H Cai, et al.
Journal of Medicinal Chemistry|October 1, 1987
Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-dionesD L Boger, M Yasuda, L A Mitscher, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Fatty acid amide hydrolase substrate specificityD L Boger, R A Fecik, J E Patterson, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|October 1, 1985
Antimicrobial and cytotoxic properties of 9,10-dihydrophenanthrenes: structure-activity studies on juncusolD L Boger, L A Mitscher, M D Mullican, et al.
Bioorganic & Medicinal Chemistry|September 26, 2000
Assessment of solution-phase positional scanning libraries based on distamycin A for the discovery of new DNA binding agentsD L Boger, M A Dechantsreiter, T Ishii, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 1999
Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicityP G Baraldi, B Cacciari, R Romagnoli, et al.
Journal of the American Chemical Society|June 21, 2001
A simple, high-resolution method for establishing DNA binding affinity and sequence selectivityD L Boger, B E Fink, S R Brunette, et al.
Bioorganic & Medicinal Chemistry|July 1, 1993
Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunitD L Boger, D S Johnson, M S Palanki, et al.
Bioorganic & Medicinal Chemistry|November 14, 1997
Functionalized analogues of 5,8,10-trideazafolate: development of an enzyme-assembled tight binding inhibitor of GAR Tfase and a potential irreversible inhibitor of AICAR TfaseD L Boger, N E Haynes, M S Warren, et al.
Bioorganic & Medicinal Chemistry|November 14, 1997
Multisubstrate analogue based on 5,8,10-trideazafolateD L Boger, N E Haynes, M S Warren, et al.
Biochemistry|December 22, 1999
New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with beta-GAR and 10-formyl-5,8,10-trideazafolic acidS E Greasley, M M Yamashita, H Cai, et al.
Journal of Medicinal Chemistry|October 1, 1987
Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-dionesD L Boger, M Yasuda, L A Mitscher, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Fatty acid amide hydrolase substrate specificityD L Boger, R A Fecik, J E Patterson, et al.
Pageof 9